FDA Approves Nivolumab Plus Ipilimumab with Chemotherapy for NSCLC

The FDA approved the use of nivolumab plus ipilimumab given with 2 cycles of platinum-doublet chemotherapy as a first-line treatment for adult patients with metastatic or recurrent non-small cell lung cancer.

Source: CancerNetwork - May 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news